Aurisco(605116)2025-04-25 10:50Financial Performance - The company's operating revenue for 2024 reached ¥1,475,741,034.67, representing a year-on-year increase of 16.89% compared to ¥1,262,530,882.14 in 2023[23]. - The net profit attributable to shareholders for 2024 was ¥354,792,033.04, which is a 22.59% increase from ¥289,419,389.73 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥350,966,371.48, up 34.25% from ¥261,425,250.85 in 2023[23]. - The basic earnings per share for 2024 was ¥0.89, reflecting a 25.35% increase from ¥0.71 in 2023[24]. - The total assets of the company as of the end of 2024 were ¥3,877,422,385.61, a significant increase of 50.60% from ¥2,574,610,570.52 in 2023[23]. - The weighted average return on equity for 2024 was 17.35%, an increase of 1.26 percentage points from 16.09% in 2023[25]. - The cash flow from operating activities for 2024 was ¥332,405,825.62, down 13.80% from ¥385,605,552.66 in 2023[23]. - The company reported a net profit of ¥82,184,172.26 in Q1 2024, with total revenue of ¥335,623,155.40 for the same period[26]. - The company recorded a net profit of ¥106,407,908.48 in Q2 2024, with revenue of ¥395,033,849.16[26]. - The company achieved a revenue of 1.476 billion yuan in 2024, a year-on-year increase of 16.89%, and a net profit of 355 million yuan, up 22.59% from the previous year[31]. Dividend Policy - The company plans to distribute a cash dividend of RMB 2.90 per 10 shares (including tax), totaling approximately RMB 117,796,550.00, which accounts for 33.20% of the net profit attributable to shareholders for the year 2024[6]. - The company has maintained a consistent cash dividend policy, distributing at least 20% of the distributable profit as cash dividends annually when conditions permit[153][155]. - Over the last three fiscal years, the cumulative cash dividend amount (including tax) was RMB 27,215.07 million, with an average cash dividend payout ratio of 95.47% of the average annual net profit[162]. - The company has not proposed any stock dividends or capital reserve transfers for the 2024 fiscal year, opting to retain undistributed profits for future allocation[156]. - The company’s cash dividend distribution plan for 2024 has been approved by the board and is pending shareholder approval at the annual general meeting[156]. Research and Development - Research and development expenses totaled 146 million yuan, a 6.91% increase year-on-year, with 45 ongoing projects in various drug categories[34]. - The company submitted 29 invention patent applications and received 13 new authorized patents during the reporting period, enhancing its intellectual property portfolio[36]. - The company has established six major engineering technology innovation platforms, enhancing its R&D capabilities[54]. - The company’s R&D investment during the reporting period accounted for 9.92% of its operating revenue, with a net asset ratio of 6.28%[92]. - The company is investing in new product development and technology research to drive innovation and competitiveness in the market[129]. - The company plans to increase R&D expenditure to 143 million yuan in 2024, representing a year-on-year growth of 4.30%[116]. Market Expansion and Strategy - The company is actively expanding its market presence through new product development and regulatory approvals in both domestic and international markets[87]. - The company plans to continue expanding its market share and product offerings in the coming year[66]. - Market expansion plans include entering two new international markets by the end of 2024, aiming for a 30% increase in global sales[130]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million allocated for potential mergers and acquisitions[130]. - The company aims to achieve a revenue growth target of 10% in the next fiscal year, supported by new product launches and market strategies[129]. Environmental Responsibility - The company invested approximately 26.43 million yuan in environmental protection during the reporting period[171]. - The company has implemented various pollution prevention measures, including advanced wastewater and waste gas treatment systems[181][183]. - The company is committed to continuous improvement in environmental management, having obtained ISO 14001:2015 certification for its environmental management system[195]. - The company has established a comprehensive environmental risk emergency mechanism, with the emergency response plan filed with the local environmental authority[187]. - The company has installed online monitoring systems for wastewater and VOCs at discharge points, ensuring compliance with environmental standards[190]. Corporate Governance - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company has a structured decision-making process for profit distribution, requiring board approval and submission to the shareholders' meeting[154]. - The company’s management performance evaluation and incentive mechanisms are overseen by the remuneration and assessment committee of the board[166]. - The company held two shareholder meetings during the reporting period: the first extraordinary meeting in January 2024 and the annual meeting in May 2024[126]. - The company has established a structured compensation policy aimed at attracting and retaining talent, with a focus on performance-based evaluations[150]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[9]. - The company has not faced any substantial impact on its production and operations from major risks during the reporting period[9]. - The company faces risks from international trade environment changes, which could impact its export business[112]. - The company is committed to complying with new industry regulations, including "consistency evaluation of generic drug quality and efficacy" and "centralized procurement," to ensure sustainable profitability[118]. - The company faces risks from intensified competition, particularly from developed countries and emerging markets, which may adversely affect performance if competitive advantages are not maintained[117].